Executive Director, Pharmacometrics
Structure Therapeutics
Dr. Feng Yang is Executive Director and Head of the Pharmacometrics (PMx) function at Structure Therapeutics. In this leadership role, he is responsible for defining and executing model-informed drug development (MIDD) strategies across all clinical programs. He provides scientific oversight of pharmacometric analyses from IND through post-marketing stages and plays a central role in regulatory submissions and cross-functional decision-making.
Dr. Yang has deep expertise in developing quantitative models to characterize pharmacokinetics and pharmacodynamics, supporting trial design, dose selection, and therapeutic optimization. He also leads the integration of data science and advanced modeling approaches, including real-world data, physiologically based pharmacokinetics (PBPK), and machine learning tools.
Prior to joining Structure, Dr. Yang held positions of increasing responsibility at Eli Lilly, Regeneron, and AstraZeneca Pharmaceuticals. He earned his Ph.D. in Chemical Engineering from the University of Rhode Island and completed postdoctoral training at the Medical College of Wisconsin.
Thursday, May 29, 2025
12:15 PM - 1:15 PM East Coast USA Time